	US 12,338,291 B2
	Humanized antibody molecules to CD138 and uses thereof
Bharat Chaganty, Concord, MA (US); Boopathy Ramakrishnan, Braintree, MA (US); Hedy Adari-Hall, Sudbury, MA (US); Karthik Viswanathan, Acton, MA (US); James R. Myette, Waltham, MA (US); Zachary Shriver, Winchester, MA (US); and Andrew M. Wollacott, Milton, MA (US)
Assigned to VISTERRA, INC., Waltham, MA (US)
Filed by VISTERRA, INC., Waltham, MA (US)
Filed on Jun. 17, 2020, as Appl. No. 16/904,090.
Claims priority of provisional application 63/035,323, filed on Jun. 5, 2020.
Claims priority of provisional application 62/862,457, filed on Jun. 17, 2019.
Prior Publication US 2020/0392241 A1, Dec. 17, 2020
Int. Cl. C07K 16/30 (2006.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01); C07K 16/46 (2006.01); A61K 31/69 (2006.01); A61K 39/00 (2006.01)

CPC C07K 16/2896 (2013.01) [A61P 35/00 (2018.01); A61K 31/69 (2013.01); A61K 2039/545 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/35 (2013.01); C07K 2317/52 (2013.01); C07K 2317/565 (2013.01); C07K 2317/732 (2013.01); C07K 2317/734 (2013.01)]

21 Claims

1. A monoclonal anti-CD138 antibody molecule comprising:

(a) a heavy chain variable region (VH), wherein the VH comprises three heavy chain complementarity determining regions (HCDR1, HCDR2, and HCDR3), wherein the VH comprises an HCDR1 comprising the amino acid sequence of SEQ ID NO: 380, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 514, and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 508; and

(b) a light chain variable region (VL), wherein the VL comprises three light chain complementarity determining regions (LCDR1, LCDR2, and LCDR3), wherein the VL comprises an LCDR1 comprising the amino acid sequence of SEQ ID NO: 510, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 353, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 354.